Cumberland Pharmaceuticals Stock One Year Return
| CPIX Stock | USD 2.40 0.04 1.64% |
Cumberland Pharmaceuticals fundamentals help investors to digest information that contributes to Cumberland Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cumberland Stock. The fundamental analysis module provides a way to measure Cumberland Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cumberland Pharmaceuticals stock.
Cumberland | One Year Return |
Cumberland Pharmaceuticals Company One Year Return Analysis
Cumberland Pharmaceuticals' One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Cumberland One Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Cumberland Pharmaceuticals is extremely important. It helps to project a fair market value of Cumberland Stock properly, considering its historical fundamentals such as One Year Return. Since Cumberland Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cumberland Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cumberland Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
| Competition |
Cumberland Return On Tangible Assets
Return On Tangible Assets |
|
Based on the recorded statements, Cumberland Pharmaceuticals has an One Year Return of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Cumberland One Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cumberland Pharmaceuticals' direct or indirect competition against its One Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cumberland Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cumberland Pharmaceuticals by comparing valuation metrics of similar companies.Cumberland Pharmaceuticals is currently under evaluation in one year return category among its peers.
Cumberland Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cumberland Pharmaceuticals from analyzing Cumberland Pharmaceuticals' financial statements. These drivers represent accounts that assess Cumberland Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cumberland Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 79.3M | 44.7M | 69.6M | 25.6M | 29.4M | 28.0M | |
| Enterprise Value | 72.6M | 37.1M | 58.6M | 25.7M | 29.6M | 28.1M |
Cumberland Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cumberland Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cumberland Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Cumberland Fundamentals
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0564 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 21.36 M | ||||
| Shares Outstanding | 14.04 M | ||||
| Shares Owned By Insiders | 44.80 % | ||||
| Shares Owned By Institutions | 14.68 % | ||||
| Number Of Shares Shorted | 89.61 K | ||||
| Price To Earning | (16.05) X | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 0.47 X | ||||
| Revenue | 39.55 M | ||||
| Gross Profit | 32.89 M | ||||
| EBITDA | 153.32 K | ||||
| Net Income | (6.28 M) | ||||
| Cash And Equivalents | 18.22 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 18.43 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 1.80 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 6.09 M | ||||
| Short Ratio | 1.20 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 91 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 17.41 M | ||||
| Total Asset | 81.78 M | ||||
| Retained Earnings | (17.49 M) | ||||
| Working Capital | 7.73 M | ||||
| Current Asset | 66.96 M | ||||
| Current Liabilities | 11.69 M | ||||
| Net Asset | 81.78 M |
About Cumberland Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cumberland Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cumberland Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cumberland Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.